-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Granahan Investment Management LLC Buys 691,029 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)
Granahan Investment Management LLC Buys 691,029 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)
Granahan Investment Management LLC boosted its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) by 54.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,957,719 shares of the biotechnology company's stock after purchasing an additional 691,029 shares during the quarter. Granahan Investment Management LLC owned about 0.89% of ImmunoGen worth $9,319,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Xponance Inc. bought a new stake in shares of ImmunoGen in the first quarter valued at approximately $49,000. HighTower Advisors LLC acquired a new position in shares of ImmunoGen in the fourth quarter valued at $77,000. O Shaughnessy Asset Management LLC raised its stake in shares of ImmunoGen by 68.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,620 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 5,115 shares in the last quarter. XTX Topco Ltd acquired a new position in ImmunoGen during the first quarter worth $62,000. Finally, TFC Financial Management raised its stake in ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 2,750 shares in the last quarter. Institutional investors own 95.58% of the company's stock.
Get ImmunoGen alerts:Analyst Upgrades and Downgrades
IMGN has been the subject of several recent analyst reports. Barclays initiated coverage on ImmunoGen in a research note on Friday. They set an "overweight" rating and a $8.00 price objective for the company. StockNews.com lowered ImmunoGen from a "hold" rating to a "sell" rating in a research note on Monday, August 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $9.80.
ImmunoGen Price Performance
ImmunoGen stock opened at $5.46 on Friday. The business's 50-day simple moving average is $5.39 and its 200 day simple moving average is $4.84. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -7.91 and a beta of 0.90. ImmunoGen, Inc. has a 12-month low of $3.10 and a 12-month high of $7.77.ImmunoGen (NASDAQ:IMGN – Get Rating) last posted its quarterly earnings results on Friday, July 29th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03). The firm had revenue of $14.20 million during the quarter, compared to the consensus estimate of $16.18 million. ImmunoGen had a negative net margin of 179.64% and a negative return on equity of 67.02%. ImmunoGen's revenue was down 16.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.15) EPS. As a group, sell-side analysts expect that ImmunoGen, Inc. will post -0.89 EPS for the current year.
About ImmunoGen
(Get Rating)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
See Also
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
Granahan Investment Management LLC boosted its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) by 54.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,957,719 shares of the biotechnology company's stock after purchasing an additional 691,029 shares during the quarter. Granahan Investment Management LLC owned about 0.89% of ImmunoGen worth $9,319,000 at the end of the most recent quarter.
根据Granahan Investment Management LLC最近向美国证券交易委员会(Securities&Exchange Commission)披露的信息,该公司在第一季度增持了免疫系统公司的股份(纳斯达克代码:IMGN-GET评级)54.6%。该公司在本季度额外购买了691,029股后,拥有1,957,719股这家生物技术公司的股票。截至最近一个季度末,Granahan Investment Management LLC拥有ImmunoGen约0.89%的股份,价值931.9万美元。
Other large investors have also recently added to or reduced their stakes in the company. Xponance Inc. bought a new stake in shares of ImmunoGen in the first quarter valued at approximately $49,000. HighTower Advisors LLC acquired a new position in shares of ImmunoGen in the fourth quarter valued at $77,000. O Shaughnessy Asset Management LLC raised its stake in shares of ImmunoGen by 68.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,620 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 5,115 shares in the last quarter. XTX Topco Ltd acquired a new position in ImmunoGen during the first quarter worth $62,000. Finally, TFC Financial Management raised its stake in ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 2,750 shares in the last quarter. Institutional investors own 95.58% of the company's stock.
其他大型投资者最近也增持或减持了该公司的股份。今年第一季度,Xponance Inc.购入了一批新股,价值约49,000美元。HighTower Advisors LLC在第四季度收购了ImmunoGen股票的新头寸,价值77,000美元。O Shaughnessy Asset Management LLC在第四季度将其在ImmunoGen的股份增加了68.2%。O Shaughnessy Asset Management LLC现在拥有这家生物技术公司12,620股票,价值94,000美元,上个季度又购买了5,115股票。XTX Topco Ltd在第一季度收购了免疫遗传公司的一个新头寸,价值6.2万美元。最后,TFC金融管理公司在第一季度将其在ImmunoGen的持股比例提高了18.1%。在上个季度增持了2,750股后,TFC金融管理公司现在持有这家生物技术公司17,950股股票,价值8.5万美元。机构投资者持有该公司95.58%的股票。
Analyst Upgrades and Downgrades
分析师升级和下调评级
IMGN has been the subject of several recent analyst reports. Barclays initiated coverage on ImmunoGen in a research note on Friday. They set an "overweight" rating and a $8.00 price objective for the company. StockNews.com lowered ImmunoGen from a "hold" rating to a "sell" rating in a research note on Monday, August 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $9.80.
IMGN一直是最近几份分析师报告的主题。巴克莱在周五的一份研究报告中启动了对免疫基因的报道。他们为该公司设定了“增持”评级和8.00美元的目标价。在8月1日星期一的一份研究报告中,StockNews.com将免疫系统的评级从“持有”下调至“卖出”。一名投资分析师对该股的评级为卖出,两名分析师的评级为持有,三名分析师的评级为买入。根据MarketBeat.com的数据,该公司目前的平均评级为持有,共识目标价为9.80美元。
ImmunoGen Price Performance
免疫发电性价比
ImmunoGen (NASDAQ:IMGN – Get Rating) last posted its quarterly earnings results on Friday, July 29th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03). The firm had revenue of $14.20 million during the quarter, compared to the consensus estimate of $16.18 million. ImmunoGen had a negative net margin of 179.64% and a negative return on equity of 67.02%. ImmunoGen's revenue was down 16.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.15) EPS. As a group, sell-side analysts expect that ImmunoGen, Inc. will post -0.89 EPS for the current year.
免疫基因公司(纳斯达克代码:IMGN-GET Rating)上一次公布季度收益是在7月29日星期五。这家生物技术公司公布了该季度每股收益(EPS)(0.24美元),低于普遍预期的(0.21美元)和(0.03美元)。该公司本季度营收为1,420万美元,而普遍预期为1,618万美元。免疫基因公司的净利润率为负179.64%,净资产回报率为负67.02%。免疫系统的营收同比下降了16.0%。在上一年的同一季度,该业务的每股收益为0.15美元。卖方分析师预计,作为一个整体,ImmunoGen,Inc.本年度每股收益将达到0.89美元。
About ImmunoGen
关于免疫基因
(Get Rating)
(获取评级)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
免疫基因公司是一家临床阶段的生物技术公司,开发抗体-药物结合(ADC)疗法来治疗癌症。该公司的候选产品包括针对叶酸受体α(FRA)的ADC Mirvetuximab soravtansine,它正处于治疗对铂耐药的卵巢癌的第三阶段临床试验;以及Pivekimab Sunirine,一种针对CD123的ADC,正处于治疗急性髓系白血病和原始浆细胞样树突状细胞肿瘤的第二阶段临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于免疫基因的研究报告(IMGN)
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏,这些股票可能表现优异
- DocuSign是否即将发生重大逆转?
- 石油和天然气股票:投资可再生能源的安全途径
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫基因日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收最新新闻和分析师对免疫系统及相关公司评级的每日简明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧